Onderneming Tekmira Pharmaceuticals Corporation Toronto S.E.
Aandelen
TKM
CA87911B2093
Farmaceutische producten
Vakgebied
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Novel Therapeutics
100,0
%
| 39 | 100,0 % | 18 | 100,0 % | -53,51% |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 39 | 100,0 % | 18 | 100,0 % | -53,51% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 50 | 01-07-14 | |
David Hastings
DFI | Director of Finance/CFO | 62 | 11-06-18 |
Karen Sims
CTO | Chief Tech/Sci/R&D Officer | 53 | 01-04-17 |
Michael Sofia
CTO | Chief Tech/Sci/R&D Officer | 66 | 01-03-15 |
John Naftzger
CMP | Compliance Officer | 57 | 10-07-23 |
Investor Relations Contact | - | 21-09-21 | |
Shannon Briscoe
HRO | Human Resources Officer | - | 01-07-21 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 68 | 01-12-14 | |
James Meyers
BRD | Director/Board Member | 59 | 23-10-18 |
Daniel Burgess
BRD | Director/Board Member | 62 | 23-03-17 |
Keith Manchester
BRD | Director/Board Member | 55 | 04-03-15 |
Frank Torti
CHM | Chairman | 45 | 26-11-18 |
Chief Executive Officer | 50 | 01-07-14 | |
Director/Board Member | 54 | 12-07-23 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 188 717 409 | 146 657 129 ( 77,71 %) | 0 | 77,71 % |
Bedrijfsgegevens
![Adres Tekmira Pharmaceuticals Corporation(TKM)](https://cdn.zonebourse.com/static/address/1411938.png)
Sector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+2,99% | 95,18 mld. | |
-4,34% | 37,55 mld. | |
-10,41% | 33,75 mld. | |
+75,79% | 28,2 mld. | |
-14,61% | 15,63 mld. | |
-3,46% | 13,63 mld. | |
-12,31% | 11,5 mld. | |
+184,77% | 10,81 mld. | |
-54,13% | 9,23 mld. |